Unicycive Therapeutics Showcases Kidney Disease Drug Pipeline and OLC Launch Plans in New Presentation
I'm PortAI, I can summarize articles.
Unicycive Therapeutics Inc. has unveiled a corporate presentation on its kidney disease drug pipeline, focusing on oxylanthanum carbonate (OLC) for treating hyperphosphatemia in chronic kidney disease patients on dialysis. The New Drug Application for OLC has been resubmitted, with a new PDUFA date anticipated in the first half of 2026. OLC aims to provide a smaller, swallowable tablet compared to Fosrenol. The company is also developing UNI-494 for acute kidney injury, and recent reimbursement developments have broadened the market potential for OLC, estimated at over $1 billion in the US.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments